Phospholipase C Activator
-
pTH (1-34) amide (human)
0 ImagesPTH (1-34) amide human is a type 1 PTH/PTHrP receptor agonist. PTH (1-34) amide human activates adenylate cyclase and phospholipase C pathways, thereby mediating mineral ion homeostasis and bone metabolism regulation. PTH (1-34) amide human increases serum calcium, decreases serum phosphorus, regulates renal excretion, while inducing the inhibition of endogenous PTH (1-84) and the increase of 1,25-dihydroxyvitamin D2 and bone resorption. PTH (1-34) amide human stimulates phosphatidylcholine hydrolysis via phospholipase D mediation, and its hypercalcemic effect is inhibited by human PTH-(7-84). PTH (1-34) amide human can be used in the research of diseases related to humoral hypercalcemia of malignancy.
-
Anti-CD3 Antibody (UCHT-1)
0 ImagesCat. No.: HY-P991842Anti-CD3 Antibody (UCHT-1) is an antibody targeting CD3. Anti-CD3 Antibody (UCHT-1) activates the phospholipase C and phosphatidylinositol 3-kinase (PI3K) signaling pathways, elevates intracellular calcium levels, regulates the T3 epitope, and triggers T lymphocyte proliferation. Anti-CD3 Antibody (UCHT-1) also inhibits lymphocyte proliferation, abolishes IL-2 production, and blocks the expression of IL-2 receptors. Anti-CD3 Antibody (UCHT-1) is applicable to research related to graft-versus-host disease, acute myeloid leukemia, and B-cell acute lymphoblastic leukemia.
-
Ranakinin
0 ImagesCat. No.: HY-P2139CAS No.: 139446-71-2Ranakinin is a NK1R agonist. Ranakinin inhibits the binding of selective NK1 radioligands to NK1 receptors. Ranakinin activates phospholipase C (Phospholipase C), thereby enhancing polyphosphoinositide hydrolysis. Ranakinin stimulates inositol phosphate production and reduces membrane polyphosphoinositide levels. Ranakinin stimulates corticosterone and aldosterone secretion.
-
SHP1-IN-2
0 ImagesCat. No.: HY-186140SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by activating natural killer cells and cytotoxic CD8＋ T cells, along with reduced T cel l. SHP1‑IN‑2 can be used for cancer‑related research.
